Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-16
2006-05-16
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S391500, C530S391700, C424S130100, C424S133100, C424S141100, C424S156100, C424S179100, C424S181100, C435S070210, C435S449000
Reexamination Certificate
active
07045605
ABSTRACT:
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
REFERENCES:
patent: 4454106 (1984-06-01), Gansow et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4814275 (1989-03-01), Durda et al.
patent: 4855353 (1989-08-01), Kurami et al.
patent: 4863851 (1989-09-01), McEwan et al.
patent: 4863854 (1989-09-01), Mattes et al.
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 5013645 (1991-05-01), Kim
patent: 5053503 (1991-10-01), Dean et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5118611 (1992-06-01), Smith et al.
patent: 5130118 (1992-07-01), Johnson et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5198208 (1993-03-01), Berg et al.
patent: 5208324 (1993-05-01), Klaveness et al.
patent: 5217704 (1993-06-01), Johnson et al.
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5314996 (1994-05-01), Wright, Jr.
patent: 5342924 (1994-08-01), Chang
patent: 5419893 (1995-05-01), Berg et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5530101 (1996-06-01), Queen et al.
patent: 5531978 (1996-07-01), Berg et al.
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5565562 (1996-10-01), Parker et al.
patent: 5578484 (1996-11-01), Horoszewicz
patent: 5599677 (1997-02-01), Dowell et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5639879 (1997-06-01), Mease et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5674470 (1997-10-01), Tweedle et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5846519 (1998-12-01), Tweedle et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5935818 (1999-08-01), Israeli et al.
patent: 5958474 (1999-09-01), Lee et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6022524 (2000-02-01), Maisano et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6136311 (2000-10-01), Bander
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6200765 (2001-03-01), Murphy et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 6340701 (2002-01-01), Chari et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6649163 (2003-11-01), Bander
patent: 6770450 (2004-08-01), Bander
patent: 6824780 (2004-11-01), Devaux et al.
patent: 2003/0003101 (2003-01-01), Bander
patent: 2003/0031673 (2003-02-01), Bander
patent: 2003/0161832 (2003-08-01), Bander
patent: 733544 (2001-05-01), None
patent: 9710487 (1999-08-01), None
patent: 2261018 (1998-01-01), None
patent: 2452288 (2003-03-01), None
patent: 1244921 (2000-02-01), None
patent: 4634 (2004-06-01), None
patent: 0 208 531 (1987-01-01), None
patent: 0 232 751 (1987-08-01), None
patent: 0 233 619 (1987-08-01), None
patent: 0 279 397 (1988-08-01), None
patent: 0 292 689 (1988-11-01), None
patent: 0 299 795 (1989-01-01), None
patent: 0 315 188 (1989-05-01), None
patent: 0 382 583 (1990-08-01), None
patent: 0 392 423 (1990-10-01), None
patent: 0 466 200 AW (1992-01-01), None
patent: 0 495 878 (1992-07-01), None
patent: 0 594 739 (1994-05-01), None
patent: 0 882 454 AZ (1998-12-01), None
patent: 2002-513378 (2002-05-01), None
patent: 333683 (2001-09-01), None
patent: 524036 (2004-12-01), None
patent: WO 86/06384 (1986-11-01), None
patent: WO 88/02635 (1988-04-01), None
patent: WO 89/00557 (1989-01-01), None
patent: WO 89/06979 (1989-08-01), None
patent: WO 91/15466 (1991-10-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/19668 (1993-10-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/26297 (1994-11-01), None
patent: WO 95/26206 (1995-10-01), None
patent: WO 95/31444 (1995-11-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 96/40245 (1996-12-01), None
patent: WO 97/32862 (1997-09-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO 98/03873 (1998-01-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/43710 (1999-09-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/50457 (2000-08-01), None
patent: WO 00/52473 (2000-09-01), None
patent: WO 00/74729 (2000-12-01), None
patent: WO 02/098897 (2002-12-01), None
patent: WO 03/024388 (2003-03-01), None
US 6,290,956, 09/2001, Bander (withdrawn)
Fundamental Immunology 242, William E. Paul, M.D. ed., 3d ed. 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA 1982 vol. 79 pp. 1979-1983.
Hinman et al. Cancer Research 53:3336-23342, 1993.
Li et al. Bioconjugate Chemistry 5(2):101-104, 1994.
Liu et al. Proc. Natl. Acad. Sci. USA 93:8618-8623, 1996.
Ghosh et al. Journal of Cellular Biochemistry, 91(3):528-539, 2004.
Richstone et al. Proceedings of the American Society of Clinical Oncology, vol. 19, abstract 1329, May 20, 2000.
Barren et al. (1997), “Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells”, Prostate 30(1):65-8.
Carter et al. (1996), “Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase”, Proc. Natl. Acad. Sci. U.S.A. 93:749-751.
Chang et al. (1999), “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature”, Cancer Research, 59(13):3192-3198.
Diamond et al. (1997), “Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer”, Journal of Urology 157(4 suppl):226 (Abstract 884).
Dillman et al. (1988), “Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients”, Mol. Biother. 1(2):81-85.
Dillman et al. (1994), “Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies”, Cancer Biotherapy 9(1):17-28.
Fair et al. (1997), “Prostate Specific Membrane Antigen”, Prostate 32(2):140-8.
Goldsmith and Bander, “Monoclonal Antibody Therapy”, Nuclear Oncology: Diagnosis and Therapy. Chapter 32: Prostate Carcinoma. pp. 433-439. Lippincott Williams and Wilkins, Philadelphia, 2001.
Hamilton et al. (1998), “A novel humanized antibody against Prostate Specific Membrane Antigen (PSMA) for in vivo targeting and therapy”, Proc. Amer. Assoc. Cancer Res. 39:440, Abstract #2997.
Harlow and Lane (1988), “Antibodies: A laboratory manual”, Cold Spring Harbor Laboratory, p. 139-243.
Heston (1997), “Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase”, Urology 49(3A):104-112.
Holmes (2001), “PSMA specific antibodies and their diagnostic and therapeutic use”, Exp. Opin. Invest. Drugs 10(3):511-19.
Horoszewicz et al. (1987), “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients”, Anticancer Research 7(5B):927-936.
Israeli et al.
Bander Neil
Carr Francis J.
Hamilton Anita
Blanchard David J.
Cornell Research Foundation Inc.
Helms Larry R.
LandOfFree
Modified antibodies to prostate-specific membrane antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified antibodies to prostate-specific membrane antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antibodies to prostate-specific membrane antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3563909